Cash Flow Statement

Currency: USD

	Jun-2020	Sep-2020	Dec-2020	Mar-2021	Jun-2021	Sep-2021	Dec-2021	Mar-2022	Jun-2022	Sep-2022	Dec-2022	Mar-2023	Jun-2023	Sep-2023	Dec-2023
Operating Cash Flow
Net Income	(45)	(55)	(91)	(144)	(199)	(208)	(192)	(165)	(127)	(115)	(113)	(98)	(86)	(75)	(62)
Depreciation & Amortization	1	1	1	1	1	1	2	2	3	6	9	9	8	4	1
Stock-Based Compensation	2	3	4	5	6	8	9	9	8	7	5	5	5	5	4
Other Non-Cash Items	3	3	4	5	7	9	10	10	10	9	12	12	14	16	11
Change in Working Capital	(1)	(6)	(1)	34	65	31	9	(40)	(67)	(28)	(8)	5	(1)	0	(3)
Cash from Operating Activities	(42) N/A	(56) -34%	(87) -55%	(104) -19%	(125) -21%	(167) -33%	(171) -2%	(193) -12%	(181) +6%	(127) +30%	(100) +21%	(73) +27%	(65) +11%	(55) +15%	(53) +4%
Investing Cash Flow
Capital Expenditures	(1)	(6)	(8)	(9)	(9)	(4)	(3)	(3)	(2)	(3)	(2)	(1)	(1)	(1)	(0)
Cash from Investing Activities	(1) N/A	(6) -547%	(8) -38%	(9) -7%	(9) -2%	(4) +52%	(3) +33%	(3) +7%	(2) +8%	(3) -4%	(2) +37%	(1) +30%	(1) -26%	(1) +56%	(0) +23%
Financing Cash Flow
Net Issuance of Common Stock	136	149	248	482	369	357	234	1	2	1	0	0	0	0	0
Net Issuance of Debt	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other	0	(0)	(1)	0	0	0	0	0	0	0	0	0	0	0	0
Cash from Financing Activities	151 N/A	149 -1%	247 +65%	480 +95%	368 -23%	356 -3%	234 -34%	1 -99%	2 +57%	1 -45%	0 -62%	0 -68%	0 N/A	0 -75%	0 N/A
Change in Cash
Net Change in Cash	108 N/A	87 -20%	152 +74%	368 +143%	234 -36%	184 -21%	60 -67%	(194) N/A	(182) +6%	(129) +29%	(101) +21%	(74) +27%	(66) +10%	(56) +16%	(54) +4%
Free Cash Flow
Free Cash Flow	(43) N/A	(62) -45%	(95) -53%	(113) -18%	(134) -19%	(172) -28%	(174) -2%	(195) -12%	(184) +6%	(130) +29%	(102) +22%	(74) +27%	(67) +10%	(56) +16%	(54) +4%

Talis Biomedical Corp
NASDAQ:TLIS